AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

Core Viewpoint - AC Immune reported a quarterly loss of $0.21 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.22, indicating a 4.55% earnings surprise [1] - The company has shown mixed performance in revenue, with $1.1 million reported for the quarter, missing the consensus estimate by 3.42% [2] Financial Performance - Over the last four quarters, AC Immune has surpassed consensus EPS estimates three times [2] - The company has experienced a significant decline in share price, losing about 37% since the beginning of the year, compared to a 5.5% decline in the S&P 500 [3] Future Outlook - The future performance of AC Immune's stock will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - Current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $3.07 million, and for the current fiscal year, it is -$0.86 on revenues of $36.52 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]